Pacer Advisors Inc. Sells 166,887 Shares of Lantheus Holdings, Inc. $LNTH

Pacer Advisors Inc. decreased its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 39.5% in the 4th quarter, HoldingsChannel reports. The firm owned 255,293 shares of the medical equipment provider’s stock after selling 166,887 shares during the quarter. Pacer Advisors Inc.’s holdings in Lantheus were worth $16,990,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Smartleaf Asset Management LLC raised its holdings in shares of Lantheus by 63.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock valued at $34,000 after buying an additional 197 shares during the last quarter. Parallel Advisors LLC lifted its position in shares of Lantheus by 122.6% during the fourth quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock worth $36,000 after purchasing an additional 298 shares in the last quarter. Osterweis Capital Management Inc. bought a new stake in shares of Lantheus during the second quarter valued at approximately $36,000. Los Angeles Capital Management LLC bought a new stake in shares of Lantheus during the fourth quarter valued at approximately $39,000. Finally, Farther Finance Advisors LLC grew its stake in shares of Lantheus by 71.4% during the fourth quarter. Farther Finance Advisors LLC now owns 660 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 275 shares during the last quarter. Institutional investors own 99.06% of the company’s stock.

Lantheus Trading Up 0.1%

Shares of NASDAQ LNTH opened at $103.92 on Friday. The company’s 50 day simple moving average is $93.37 and its 200 day simple moving average is $78.24. Lantheus Holdings, Inc. has a fifty-two week low of $47.25 and a fifty-two week high of $107.99. The firm has a market capitalization of $6.77 billion, a P/E ratio of 25.04 and a beta of -0.03. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.83 and a quick ratio of 2.64.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.25 by $0.21. Lantheus had a net margin of 18.05% and a return on equity of 29.32%. The firm had revenue of $377.33 million for the quarter, compared to analysts’ expectations of $354.48 million. During the same period last year, the firm earned $1.53 earnings per share. The business’s revenue for the quarter was up 1.2% on a year-over-year basis. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. On average, analysts predict that Lantheus Holdings, Inc. will post 4.39 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on LNTH shares. Citizens Jmp boosted their price objective on shares of Lantheus from $85.00 to $115.00 and gave the stock a “market outperform” rating in a research report on Friday, May 8th. William Blair reiterated an “outperform” rating on shares of Lantheus in a research report on Tuesday, March 17th. Truist Financial reissued a “buy” rating and issued a $115.00 target price (up from $98.00) on shares of Lantheus in a research note on Monday, May 11th. Wall Street Zen downgraded Lantheus from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Finally, JonesTrading lowered Lantheus from a “buy” rating to a “hold” rating in a research note on Friday, February 27th. Eight equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $101.86.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.